Home › NDC Lookup › RxCUI directory › RxCUI 2686050

0.9 ML tocilizumab-aazg 180 MG/ML Auto-Injector [Tyenne] — RxCUI 2686050

Name: 0.9 ML tocilizumab-aazg 180 MG/ML Auto-Injector [Tyenne] (RxCUI 2686050)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2686050 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2686050

Official name0.9 ML tocilizumab-aazg 180 MG/ML Auto-Injector [Tyenne]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asTyenne 162 MG per 0.9 ML Auto-Injector; Tyenne 162 MG in 0.9 ML Auto-Injector

FDA products mapped4

Package NDCs mapped4

Reported Medicaid activity (SDUD)2,793 prescriptions · 19 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tocilizumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Tocilizumab injection is used for several serious inflammatory conditions. These include moderate to severe rheumatoid arthritis, giant cell arteritis, a lung condition tied to sys...
What conditions is this medication used for?
Yes — that's the most important thing to know. Because tocilizumab dials down your immune system, you are at real risk for serious infections like pneumonia, urinary tract infectio...
Is it true this can make me more likely to get sick? What should I watch for?

📖 Read our full Tocilizumab Injection guide →

🕸️ Concept Web — How 0.9 ML tocilizumab-aazg 180 MG/ML Auto-Injector... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 0.9 ML tocilizumab-aazg 180 MG/ML Auto-Injector [Tyenne] RxCUI 2686050 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Tocilizumab 612865 IN
- Tocilizumab-aazg 2679427 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Tyenne 2679433 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Tocilizumab Auto-Injector 2106072 SCDF
- Tocilizumab-aazg Auto-Injector 2686044 SCDFP
- Tocilizumab Injectable Product 1162729 SCDG
- Tocilizumab-aazg Injectable Product 2679429 SCDGP
- Tocilizumab Auto-Injector [Tyenne] 2686048 SBDF
- Tocilizumab-aazg Auto-Injector [Tyenne] 2686049 SBDFP
- Tyenne Injectable Product 2679435 SBDG
- Auto-Injector 1649570 DF
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 0.9 ML tocilizumab-aazg 180 MG/ML Auto-Injector 2686045 SCD
- Tocilizumab-aazg 180 MG/ML 2686043 SCDC
- Tocilizumab-aazg 180 MG/ML [Tyenne] 2686047 SBDC

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

0.9 ML tocilizumab-aazg 180 MG/ML Auto-Injector SCD · 2686045
Tocilizumab-aazg 180 MG/ML SCDC · 2686043
Tocilizumab Auto-Injector SCDF · 2106072
Tocilizumab-aazg Auto-Injector SCDFP · 2686044
Tocilizumab Injectable Product SCDG · 1162729
Tocilizumab-aazg Injectable Product SCDGP · 2679429

Brand-Name Concepts

Tocilizumab-aazg 180 MG/ML [Tyenne] SBDC · 2686047
Tocilizumab Auto-Injector [Tyenne] SBDF · 2686048
Tocilizumab-aazg Auto-Injector [Tyenne] SBDFP · 2686049
Tyenne Injectable Product SBDG · 2679435
Tyenne BN · 2679433

📦 FDA Products & Package NDCs

4 products · 4 package NDCs

4 package NDCs map to RxCUI 2686050 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
65219-0584-01	1 SYRINGE, GLASS in 1 CARTON (65219-584-01) / .9 mL in 1 SY...	TYENNE	Fresenius Kabi USA, LLC	2024-07-01
65219-0586-04	1 SYRINGE, GLASS in 1 CARTON (65219-586-04) / .9 mL in 1 SY...	TYENNE	Fresenius Kabi USA, LLC	2024-07-01
65219-0596-01	1 SYRINGE, GLASS in 1 CARTON (65219-596-01) / .9 mL in 1 SY...	TYENNE	Fresenius Kabi USA, LLC	2025-09-01
65219-0598-10	1 SYRINGE, GLASS in 1 CARTON (65219-598-10) / .9 mL in 1 SY...	TYENNE	Fresenius Kabi USA, LLC	2025-09-01

Observed labelers: Fresenius Kabi USA, LLC (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.

Per ml · median

$820.6570

Range $820.6570–$820.6570 · middle 50% $820.6570–$820.6570 · 2 NDCs

Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
Q5135	Inj, tyenne, 1 mg	2	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.